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Abstract
Aims/hypothesis A head-to-head randomised trial was conducted to evaluate hypoglycaemia safety with insulin degludec 200 U/
ml (degludec U200) and insulin glargine 300 U/ml (glargine U300) in individuals with type 2 diabetes treated with basal insulin.
Methods This randomised (1:1), open-label, treat-to-target, multinational trial included individuals with type 2 diabetes, aged ≥18 years
with HbA1c ≤80 mmol/mol (9.5%) and BMI ≤45 kg/m
2. Participants were previously treated with basal insulin with or without oral
glucose-lowering drugs (excluding insulin secretagogues) and had to fulfil at least one predefined criterion for hypoglycaemia risk. Both
degludec U200 and glargine U300 were similarly titrated to a fasting blood glucose target of 4.0–5.0 mmol/l. Endpoints were assessed
during a 36weekmaintenance period and a total treatment period up to 88weeks. Therewere three hypoglycaemia endpoints: (1) overall
symptomatic hypoglycaemia (either severe, an event requiring third-party assistance, or confirmed by blood glucose [<3.1 mmol/l] with
symptoms); (2) nocturnal symptomatic hypoglycaemia (severe or confirmed by blood glucose with symptoms, between 00:01 and
05:59 h); and (3) severe hypoglycaemia. The primary endpoint was the number of overall symptomatic hypoglycaemic events in the
maintenance period. Secondary hypoglycaemia endpoints included the number of nocturnal symptomatic events and number of severe
hypoglycaemic events during the maintenance period.
Results Of the 1609 randomised participants, 733 of 805 (91.1%) in the degludec U200 arm and 734 of 804 (91.3%) in the
glargine U300 arm completed the trial (87.3% and 87.8% completed on treatment, respectively). Baseline characteristics were
comparable between the two treatment arms. For the primary endpoint, the rate of overall symptomatic hypoglycaemia was not
significantly lower with degludec U200 vs glargine U300 (rate ratio [RR] 0.88 [95% CI 0.73, 1.06]). As there was no significant
difference between treatments for the primary endpoint, the confirmatory testing procedure for superiority was stopped. The pre-
specified confirmatory secondary hypoglycaemia endpoints were analysed using pre-specified statistical models but were now
considered exploratory. These endpoints showed a lower rate of nocturnal symptomatic hypoglycaemia (RR 0.63 [95% CI 0.48,
0.84]) and severe hypoglycaemia (RR 0.20 [95% CI 0.07, 0.57]) with degludec U200 vs glargine U300.
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Conclusions/interpretation There was no significant difference in the rate of overall symptomatic hypoglycaemia with degludec
U200 vs glargine U300 in the maintenance period. The rates of nocturnal symptomatic and severe hypoglycaemia were nomi-
nally significantly lower with degludec U200 during the maintenance period compared with glargine U300.
Trial registration ClinicalTrials.gov NCT03078478
Funding This trial was funded by Novo Nordisk (Bagsvaerd, Denmark)
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Abbreviations
Degludec U200 Insulin degludec 200 U/ml
FPG Fasting plasma glucose
Glargine U100 Insulin glargine 100 U/ml
Glargine U300 Insulin glargine 300 U/ml
MMRM Mixed model of repeated measures
OAD Oral glucose-lowering drug
PYE Person-years of exposure
RR Rate ratio
SMBG Self-measured blood glucose
Introduction
Hypoglycaemia is a known complication of insulin treatment
and is acknowledged as the main limiting factor for achieving
tight glycaemic control [1, 2]. The two most recently devel-
oped second-generation, longer-acting basal insulins, insulin
degludec and insulin glargine 300 U/ml (glargine U300), have
flatter and more stable steady-state pharmacokinetic and phar-
macodynamic profiles compared with long-acting insulin
glargine 100 U/ml (glargine U100) [3–6]. Insulin degludec
has a lower day-to-day variability in glucose-lowering effect
compared with glargine U100 and glargine U300 [6, 7],
whereas there are contradictory reports regarding within-day
variability when comparing insulin degludec and glargine
U300 [7, 8].
Insulin degludec and glargine U300 have been shown to be
associated with a lower risk of hypoglycaemia, at equivalent
glycaemic control compared with glargine U100 in individ-
uals with type 2 diabetes [9–20]. Glargine U300 is a concen-
trated formulation of glargine U100 and has also been shown
to be as effective as glargine U100 in terms of glycaemic
control in individuals with type 2 diabetes, but with a higher
(12–14%) basal insulin dose requirement [14–20]. Recent
results in insulin-naive individuals with type 2 diabetes
revealed similar HbA1c reductions for insulin degludec and
glargine U300 [21]. This trial also reported a similar overall
Research in context
What is already known about this subject?
 Minimising hypoglycaemia is important for people with type 2 diabetes using insulin  
 Use of second-generation long-acting basal insulins, insulin degludec 200 U/ml (degludec U200) and insulin
glargine 300 U/ml (glargine U300), compared with insulin glargine 100 U/ml (glargine U100), has been shown to
result in a lower risk of hypoglycaemia   
What is the key question?
 Is there a diference in the risk of hypoglycaemia with degludec U200 compared with glargine U300 in insulin-
treated patients with type 2 diabetes when similarly titrated to a target fasting blood glucose of 4.0–5.0 mmol/l?  
What are the new findings?
 There was no signiicant diference in the rate of overall symptomatic hypoglycaemia with degludec U200 vs
glargine U300 in the maintenance period in insulin-treated individuals  
 The rates of nocturnal symptomatic and severe hypoglycaemia were nominally signiicantly lower with degludec
U200 compared with glargine U300 during the maintenance period   
How might this impact on clinical practice in the foreseeable future?
 Results from the CONCLUDE trial add to the published literature on the latest basal insulins, degludec U200 and
glargine U300, informing healthcare providers and health systems on how to achieve blood glucose targets for
their patients more safely     
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risk of hypoglycaemia between the two insulins and a lower
rate of hypoglycaemia in the titration period with glargine
U300 vs insulin degludec, while no evaluation of severe
hypoglycaemia was conducted as only one event was record-
ed during the trial. In addition, the dose of insulin degludec
was lower than the dose of glargine U300 at the end of the trial
by 0.11 U/kg.
The primary objective of the Trial Comparing the Efficacy
and Safety of Insulin Degludec and Insulin Glargine 300
Units/ml in Subjects with Type 2 Diabetes Mellitus
Inadequately Treated with Basal Insulin and Oral
Antidiabetic Drugs (CONCLUDE), a randomised head-to-
head clinical trial, was to investigate the effect of insulin
degludec 200 U/ml (degludec U200) and glargine U300 on
hypoglycaemia in insulin-treated individuals with type 2
diabetes.
Methods
Trial design
Detailed methods of CONCLUDE have been described previ-
ously [22]. Briefly, this was a treat-to-target, randomised,
open-label, active comparator-controlled trial that was
conducted at 229 sites in 11 countries. The original 58 week
trial duration comprised 52 weeks of active treatment with
designation of the first 16 weeks as the titration period and
the remaining 36 weeks as the maintenance period (hereafter
referred to as the ‘variable maintenance period’). In February
2018, a protocol amendment led to the extension of the trial,
resulting in a total trial duration of up to 94 weeks with up to
88 weeks of active treatment, including a new maintenance
period (hereafter referred to as the ‘maintenance period’) of
36 weeks. A detailed rationale for this amendment has been
published previously [22] and the key reasons for the amend-
ment are outlined in ESM Fig. 1. In brief, routine monitoring
of blinded data showed an unusual pattern in the reporting of
glycaemic variables and hypoglycaemic events. Specifically,
the glycaemic data were inconsistent between central-
laboratory-measured variables (HbA1c and fasting plasma
glucose [FPG]) and patient-reported fasting self-measured
blood glucose (SMBG) values. Data available from SMBG
monitoring indicated to the patient that the blood glucose
levels were higher than they actually were, potentially increas-
ing the risk of hypoglycaemia as a result of unnecessary insu-
lin up-titration. At the time of the amendment, the number of
patient-reported hypoglycaemic events confirmed by blood
glucose was low whi le the number of pseudo-
hypoglycaemic events (blood glucose >3.9 mmol/l with
symptoms) was high compared with the SWITCH 2 trial
(comparing the effect of insulin degludec vs insulin glargine
U100 on in individuals with type 2 diabetes) [10]. These
observations, seen in general across the entire trial population,
were related to the glycaemic data collection system
(MyGlucoHealth blood glucose meter and electronic diary).
Therefore, because of these safety concerns, the glycaemic
data collection system was discontinued during the variable
maintenance period. This system was replaced with an Abbott
blood glucose meter and paper diary to be used for the remain-
der of the trial. To accommodate these changes, preserve the
scientific integrity of the trial and ensure sufficient data collec-
tion for the confirmatory endpoints using the same glycaemic
data collection system (Abbott blood glucose meter and paper
diary), a new 36 week maintenance period was included in the
trial. At the time of the amendment, recruitment had been
finalised and all participants on treatment had completed the
titration period. The duration of the variable maintenance peri-
od was dependent on each participant’s individual
randomisation date and/or approval of the amended protocol
by health authorities and local ethics committees, if applica-
ble. After implementation of the amended protocol, partici-
pants were asked to come in and initiate the maintenance
period as soon as the resources were available at the trial site,
irrespective of the next planned visit. Thus, all participants
were not required to have all visits scheduled between weeks
16 and 52. The trial data remained blinded at the point of
discovering the issue with the glycaemic data collection
system and the implementation of the protocol amendment.
No unplanned interim analysis of the trial data from the titra-
tion period was conducted. The primary endpoint (number of
severe or blood-glucose-confirmed symptomatic
hypoglycaemic events) at the completion of the maintenance
period was evaluated utilising the same analysis duration and
statistical methods as the original protocol. Changes were
implemented to maintain participant safety and protect the
scientific integrity of the trial.
CONCLUDE is registered with ClinicalTrials.gov no.
NCT03078478. The trial was conducted in accordance with
the Declaration of Helsinki and ICH Good Clinical Practice
Guideline [23, 24]. The protocol was approved by
independent ethics committees or institutional review boards
for each centre; written informed consent was obtained from
each participant before any trial-related activities.
Participants and treatments
Eligible participants included adults aged >18 years with type 2
diabetes with HbA1c ≤80 mmol/mol (9.5%), BMI ≤45 kg/m
2
and treated with basal insulin (once or twice daily; NPH insu-
lin, insulin detemir, glargine U100) with or without oral
glucose-lowering drugs (OADs) at stable doses (any combina-
tion of metformin, dipeptidyl peptidase-4 inhibitor, α-
glucosidase inhibitor, thiazolidinedione and sodium–glucose
cotransporter 2 inhibitor) for at least 90 days. In addition,
participants had to fulfil at least one risk criterion for
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hypoglycaemia [22]. The main exclusion criteria were treat-
ment with bolus or premixed insulin or with sulfonylureas/
glinides within 90 days before the screening visit, severe renal
impairment (eGFR <30 ml min−1 [1.73 m]−2), or impaired liver
function (alanine aminotransferase or aspartate aminotransfer-
ase ≥2.5 times the upper limit of normal).
Consenting participants were randomised using a trial-
specific, interactive-voice, web-response system.
Participants were randomised 1:1 to receive degludec
U200 (Novo Nordisk, Bagsvaerd, Denmark; the 100 U/
ml and 200 U/ml concentrations of degludec are bioequiv-
alent and interchangeable [25–27]) or glargine U300
(Sanofi, Paris, France) administered once daily. Within
each treatment arm, participants were randomised 1:1 to
administer basal insulin either in the morning (from
waking to breakfast) or in the evening (from main evening
meal to bedtime). The same dosing time was maintained
for each participant throughout the trial. When initiating
degludec U200, the pre-trial daily basal insulin dose was
reduced by 20%, as per the protocol, irrespective of prior
insulin type. Glargine U300 was initiated according to its
label: unit-to-unit switch for participants on once-daily
basal insulin; 20% reduction for those on twice-daily
NPH insulin (US patients) or any twice-daily basal insulin
(European and Canadian patients). The insulin dose was
titrated similarly for both insulins: once-weekly titration
was based on the mean of three pre-breakfast SMBG
measurements, with a fasting blood glucose target of
4.0–5.0 mmol/l. The insulin dose was adjusted in multi-
ples of 2 U ranging from −4 U to +8 U depending on the
mean pre-breakfast SMBG level [22]. The type and dose
of pre-trial OADs remained unchanged throughout the
trial unless safety reasons required a change.
Endpoints
The primary endpoint was the rate of overall symptom-
atic hypoglycaemic events (defined as severe [an event
requiring third-party assistance [28]] or confirmed blood
glucose <3.1 mmol/l [with symptoms]) during the main-
tenance period. Secondary confirmatory hypoglycaemia
endpoints included the rate of nocturnal symptomatic
hypoglycaemic events (severe or blood-glucose-
confirmed with symptoms, occurring between 00:01
and 05:59 h) and the rate of severe hypoglycaemic
events during the maintenance period. Overall symptom-
atic, nocturnal symptomatic and severe hypoglycaemic
events were also assessed during the total treatment
period (up to 88 weeks) as secondary endpoints. Other
secondary endpoints included change from baseline to
end of treatment in HbA1c level and FPG level, basal
insulin dose at the end of treatment, pre-breakfast
SMBG level and body weight. The composite endpoints
HbA1c <53 mmol/mol (7.0%) with no overall symptom-
atic hypoglycaemia and HbA1c <53 mmol/mol (7.0%)
with no nocturnal symptomatic hypoglycaemia were
assessed during the maintenance period. The number
of adverse events between the two treatment arms was
also assessed during the trial period. An independent
external event adjudication committee validated the
following selected adverse events in a blinded manner:
fatal events and severe hypoglycaemia.
Statistical analysis
The statistical analyses of the primary and secondary
endpoints have been described previously [22]. Endpoints
related to hypoglycaemia and safety endpoints were
summarised using the safety analysis set; efficacy endpoints
were summarised using the full analysis set. Statistical supe-
riority testing of the primary and confirmatory secondary
endpoints was performed following a hierarchical testing
procedure to control the family-wise type I error rate in the
strong sense and has been described previously [22]. The
sample size was calculated to ensure at least 80% power for
the primary endpoint analysis.
A negative binomial model with pre-trial OADs,
region, sex and dosing time as fixed effects, age as covar-
iate and logarithm of the exposure time as offset was used
to estimate the rate ratio (RR) of hypoglycaemic events
during the maintenance and total treatment periods.
Participants with no on-treatment data during the mainte-
nance period had values imputed for the maintenance
period analyses based on participants discontinuing treat-
ment during the maintenance period. Multiple imputations
were performed using standard methods aligned with the
analyses and planned to create 1000 complete datasets.
The results were then combined using Rubin’s methods
[29]. The proportion of participants experiencing
hypoglycaemic events was analysed post hoc using a
logistic regression model. The model included treatment,
pre-trial OADs, region, sex and dosing time as fixed
effects and age as a covariate, and logarithm of the expo-
sure time as offset. Change from baseline to end of treat-
ment in HbA1c levels, FPG levels, SMBG and body
weight were analysed post hoc using mixed models for
repeated measures (MMRM) with treatment, pre-trial
OADs, region, sex and dosing time as fixed effects, and
age and baseline HbA1c/FPG as covariates. Pre-specified
sensitivity analyses were also conducted to test the prima-
ry and protocol-specified confirmatory secondary
hypoglycaemia endpoints without imputed data as well
as capping the number of hypoglycaemic events at three.
Further post hoc sensitivity analyses controlling for vari-
ation across sites were conducted for HbA1c and FPG.
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Results
Participants
Of the 2008 eligible participants screened, 1609 were
randomised to receive either degludec U200 (n = 805) or
glargine U300 (n = 804) (Fig. 1). A total of 1467 participants
(91.2%) completed the trial of whom 1409 (87.6%) completed
the trial on treatment. The proportion of participants with-
drawing from the trial and discontinuing treatment premature-
ly was similar for both treatment groups. The protocol
amendment did not have an apparent impact on participant
retention rates (Fig. 1).
The characteristics of the participants at baseline were simi-
lar in the two treatment groups (Table 1) and did not differ
between the randomised population and those entering the
maintenance period (ESM Table 1). The mean age was
62.8 years, the mean duration of diabetes was 15.1 years,
and the mean±SD HbA1c level was 59.2 ± 10.5 mmol/mol
(7.6 ± 1.0%). At screening, most participants were using
glargine U100 (65.0%) and were treated with metformin
(77.5%).
2008 Patients assessed for eligibility
1609 Randomised
805 FAS
802 SAS
733 (91.1%) Completed trial
703 (87.3%) Completed trial on-treatment
734 (91.3%) Completed trial
706 (87.8%) Completed trial on-treatment
805 (100.0%) Randomised to degludec U200
403 Morning dose
402 Evening dose
802 Exposed
804 (100.0%) Randomised to glargine U300
402 Morning dose
402 Evening dose
798 Exposed
60 Treatment discontinuation
13 Adverse event
7 Protocol deviation
5 Lack of efficacy
35 Other
47 Withdrawn from trial
36 Withdrawal by patient
7 Lost to follow-up
3 Death
1 Not collected
39 Treatment discontinuation
10 Adverse event
7 Protocol deviation
3 Lack of efficacy
19 Other
25 Withdrawn from trial
18 Withdrawal by patient
3 Lost to follow-up
4 Death
57 Treatment discontinuation
8 Adverse event
7 Protocol deviation
8 Lack of efficacy
34 Other
43 Withdrawn from trial
b
36 Withdrawal by patient
4 Lost to follow-up
3 Death
0 Not collected
35 Treatment discontinuation
9 Adverse event
3 Protocol deviation
5 Lack of efficacy
18 Other
25 Withdrawn from trial
13 Withdrawal by patient
6 Lost to follow-up
6 Death
758 (94.2%) Entered maintenance periodc
742 (92.2%) Entered maintenance periodc on-treatment
759 (94.4%) Entered maintenance period
c
741 (92.2%) Entered maintenance period
c
 on-treatment
399 Excluded (ineligible)
a
278 Did not meet inclusion criteria
134 Met exclusion criteria
804 FAS
798 SAS
Fig. 1 Patient disposition. aSome participants fulfilled more than one
inclusion or exclusion criterion. bTwo additional participants
discontinued treatment before the protocol amendment and neither with-
drew nor re-consented. cNew, 36 week maintenance period (52–
88 weeks). The number of participants who entered the maintenance
period = (participants randomised) – (participants withdrawn from the
trial). The number of participants who entered the maintenance period
on-treatment = (participants exposed) – (participants who discontinued
treatment). The number of participants who completed trial = (partici-
pants who entered the maintenance period) – (participants withdrawn
from the trial). The number of participants who completed trial on-treat-
ment = (participants who entered the maintenance period on treatment) –
(participants who discontinued treatment). Exposed was defined as
‘randomised and received treatment’. The number of participants that
discontinued treatment includes the number that withdrew from the trial.
FAS, full analysis set; SAS, safety analysis set
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Hypoglycaemia endpoints
Overall symptomatic hypoglycaemia For the primary
endpoint, overall symptomatic hypoglycaemia, the rate was
not significantly lower with degludec U200 compared with
glargine U300 during the maintenance period (RR 0.88
[95%CI 0.73, 1.06]) (Fig. 2). Because there was no significant
difference between treatments for the primary endpoint, the
confirmatory testing procedure for superiority was stopped.
The pre-specified confirmatory secondary hypoglycaemia
endpoints, nocturnal symptomatic and severe hypoglycaemia
during the maintenance period, could not be controlled for the
family-wise type I error and therefore were now considered
exploratory. The sensitivity analyses conducted to test the
Table 1 Baseline characteristics of participants
Characteristic Degludec U200
(N = 805)
Glargine U300
(N = 804)
p value
Age, years 62.9 ± 10.0 62.8 ± 10.0 0.8599
Men 472 (58.6) 436 (54.2) 0.0785
Hispanic or Latino ethnicity 84 (10.4) 100 (12.4) 0.2111
Race 0.6978
White 693 (86.1) 699 (86.9)
Black or African-American 78 (9.7) 65 (8.1)
Asian 25 (3.1) 29 (3.6)
Other 9 (1.1) 11 (1.4)
Diabetes duration, years 15.1 ± 8.2 15.0 ± 8.4 0.7676
Oral glucose-lowering treatmenta 715 (88.8) 708 (88.1) 0.5835
Metformin 622 (77.3) 625 (77.7)
Dipeptidyl peptidase-4 inhibitor 178 (22.1) 152 (18.9)
SGLT-2 inhibitor 150 (18.6) 153 (19.0)
Combination of glucose-lowering treatmentsb 41 (5.1) 44 (5.5)
Thiazolidinedione 37 (4.6) 25 (3.1)
α-Glucosidase inhibitors 6 (0.7) 2 (0.2)
Basal insulin 803 (99.8)c 804 (100.0) 0.1014
Detemir 171 (21.2) 139 (17.3)
Glargine U100 505 (62.7) 541 (67.3)
NPH insulin 127 (15.8) 124 (15.4)
Basal insulin dose, U 42.7 ± 29.5 42.2 ± 29.1 0.7077
Body weight, kg 91.6 ± 18.1 90.6 ± 17.9 0.2396
BMI, kg/m2 31.7 ± 5.3 31.5 ± 5.2 0.5119
HbA1c, mmol/mol 59.0 ± 10.8 59.4 ± 10.2 0.5137
HbA1c, % 7.6 ± 1.0 7.6 ± 0.9 0.5137
FPG, mmol/l 7.9 ± 2.6 8.0 ± 2.6 0.6205
eGFR based on CKD-EPId, ml min−1 [1.73 m]−2 78.8 ± 21.2 80.0 ± 20.6 0.2422
Participants fulfilling ≥1 of the following hypoglycaemia risk inclusion criteria
≥1 severe hypoglycaemic event within the last year 50 (6.2) 48 (6.0)
Moderate chronic renal failure 152 (18.9) 132 (16.4)
Hypoglycaemia symptom unawareness 166 (20.6) 141 (17.5)
Exposed to insulin for ≥5 years 406 (50.4) 391 (48.6)
Hypoglycaemic event within last 12 weeks 466 (57.9) 479 (59.6)
Data are for the full analysis set and are shown as n (%) or mean±SD; percentage refers to the proportion of participants on degludec U200 or glargine
U300 treatment. The p value was determined by two-sided test of no difference
aOne participant on sulfonylurea was randomised in error and discontinued treatment
bThe combinations of glucose-lowering treatments includes allowed combinations, as per the inclusion criteria, only
cOne participant who was on premix NPH insulin and one patient who was insulin-naive were randomised in error
dTaken at screening
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; SGLT-2, sodium–glucose cotransporter 2
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primary endpoint without imputed data and capping the
number of hypoglycaemic events at three showed similar
results to the main analysis (ESM Table 2).
The proportion of participants experiencing overall symp-
tomatic hypoglycaemia during the maintenance period was
lower for those treated with degludec U200 (40.6%)
compared with glargine U300 (46.3%): OR 0.79 (95% CI
0.64, 0.97), post hoc analysis (Fig. 3). During the total treat-
ment period, the rate and the proportion of participants (post
hoc) experiencing overall symptomatic hypoglycaemia was
lower with degludec U200 vs glargine U300 (Figs 2 and 3).
Nocturnal symptomatic hypoglycaemia The rate of nocturnal
symptomatic hypoglycaemia was lower with degludec U200
compared with glargine U300 during the maintenance period
(RR 0.63 [95% CI 0.48, 0.84]) (Fig. 2). The sensitivity
analyses conducted to test this endpoint without imputed data
and capping the number of hypoglycaemic events at three
showed similar results (ESM Table 2). The proportion of
participants during the maintenance period experiencing
nocturnal symptomatic hypoglycaemia was lower for those
treated with degludec U200 (17.8%) compared with glargine
U300 (24.8%): OR 0.65 (95% CI 0.50, 0.83), post hoc anal-
ysis (Fig. 3). Similar results were observed during the total
treatment period for the rate and the proportion of participants
(pos t hoc) exper iencing nocturna l symptomat ic
hypoglycaemia (Figs 2 and 3).
Severe hypoglycaemia The rate of severe hypoglycaemia was
lower with degludec U200 compared with glargine U300
during the maintenance period (RR 0.20 [95% CI 0.07,
0.57]) (Fig. 2). The sensitivity analyses conducted to test this
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Severe
Degludec U200
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glargine U300
RR (95% CI)
0.88 (0.73, 1.06)
0.63 (0.48, 0.84)
0.20 (0.07, 0.57)
0.77 (0.65, 0.92)
(0.44, 0.74)
0.38 (0.21, 0.70)
Degludec
U200
E Rate
1110 216.8
319 62.3
5 1.0
1537 137.8
412 36.9
23 2.1
Glargine
U300
E Rate
1249 243.9
480 93.8
25 4.9
1821 163.7
668 60.0
58 5.2
Favours degludec U200
0.0625 0.125 0.25 0.5 1 2
Favours glargine U300
Fig. 2 The rate of
hypoglycaemia. Overall
symptomatic hypoglycaemia was
defined as severe hypoglycaemia
(an event requiring third-party
assistance as per the ADA
definition [28]) or blood glucose
<3.1 mmol/l confirmed with
symptoms. Nocturnal
symptomatic hypoglycaemia was
defined as severe hypoglycaemia
or blood glucose <3.1 mmol/l
confirmed with symptoms,
occurring between 00:01 and
05:59 h. aPrimary endpoint. E,
events; rate, events per 100
person-years of observation
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Fig. 3 The proportion of participants with hypoglycaemia (post hoc).
Overall symptomatic hypoglycaemia was defined as severe
hypoglycaemia (an event requiring third-party assistance as per the
ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with
symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe
hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms,
occurring between 00:01 and 05:59 h. %, proportion of participants with
events; n, number of participants experiencing events
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endpoint without imputed data and capping the number of
hypoglycaemic events at three showed similar results (ESM
Table 2). In addition, the proportion of participants experienc-
ing severe hypoglycaemia was lower for those treated with
degludec U200 (0.5%) than for those treated with glargine
U300 (2.7%): OR 0.19 (95% CI 0.07, 0.57), post hoc analysis
(Fig. 3). Similar results were observed during the total treat-
ment period for the rate and the proportion of participants
(post hoc) experiencing severe hypoglycaemia (Figs 2 and 3).
Hypoglycaemia during titration and variable maintenance
periods The rates and the proportions of participants (post
hoc) experiencing hypoglycaemia during the titration and
variable maintenance periods are shown in Figs 4 and 5.
Glycaemic control
The observed mean HbA1c values at the end of the titration
period were 50.2 mmol/mol (6.8%) with degludec U200 and
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Fig. 4 Hypoglycaemia endpoints during the titration period. Overall
symptomatic hypoglycaemia was defined as severe hypoglycaemia (an
event requiring third-party assistance as per the ADA definition [28]) or
blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symp-
tomatic hypoglycaemia was defined as severe hypoglycaemia or blood
glucose <3.1mmol/l confirmed with symptoms, occurring between 00:01
and 05:59 h. %, proportion of participants with events; E, events; n,
number of participants with events; rate, events per 100 person-years of
observation
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Proportion of participants with hypoglycaemia
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Severe
Degludec U200
vs
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RR (95% CI)
0.76 (0.60, 0.97)
0.45 (0.31, 0.66)
0.57 (0.24, 1.38)
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Fig. 5 Hypoglycaemia endpoints during the variable maintenance
period. Overall symptomatic hypoglycaemia was defined as severe
hypoglycaemia (an event requiring third-party assistance as per the
ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with
symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe
hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms,
occurring between 00:01 and 05:59 h. %, proportion of participants with
events; E, events; n, number of participants with events; rate, events per
100 person-years of observation
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50.9 mmol/mol (6.8%) with glargine U300. At the end of
treatment, the observed mean HbA1c was 52.8 mmol/mol
(7.0%) and 54.1 mmol/mol (7.1%) for degludec U200 and
glargine U300, respectively. An analysis of HbA1c demon-
strated a reduction in the HbA1c level from baseline to the
end of treatment with degludec U200 compared with glargine
U300: observed mean −5.90 mmol/mol (−0.54%) vs
−5.04 mmol/mol (−0.46%); estimated treatment difference
−1.07 mmol/mol (95% CI −1.94, −0.20) (−0.10% [95% CI
−0.18, −0.02]), post hoc analysis (Fig. 6a). At the end of
treatment, the observed mean FPG was 5.9 mmol/l and
6.5 mmol/l for degludec U200 and glargine U300, respective-
ly. There was also a reduction in FPG from baseline to the end
of treatment with degludec U200 compared with glargine
U300: observed mean −1.97 mmol/l vs −1.43 mmol/l; esti-
mated treatment difference −0.62 mmol/l (95% CI −0.82,
−0.43), post hoc analysis (Fig. 6b). Sensitivity analyses
controlling for variation across study sites were conducted
for HbA1c and FPG and showed similar results to the main
analysis (ESM Table 3). Over 88 weeks, pre-breakfast SMBG
values were similar in the two treatment groups, decreasing
during the titration period and then levelling off (estimated
treatment difference −0.18 mmol/l [95% CI −0.37, 0.01], post
hoc analysis) (Fig. 6c).
At the end of the maintenance period, 35.3% of
participants treated with degludec U200 vs 30.0% of
participants treated with glargine U300 achieved a
composite endpoint of HbA1c <53 mmol/mol (7.0%)
with no overall symptomatic hypoglycaemia (OR 1.31
[95% CI 1.04, 1.65], post hoc analysis). Similarly,
47.4% of participants treated with degludec U200
achieved an HbA1c <53 mmol/mol (7.0%) with no
nocturnal symptomatic hypoglycaemia compared with
39.3% of participants treated with glargine U300 (OR
1.23 [95% CI 0.99, 1.54], post hoc analysis).
Insulin dose
The observedmean±SD baseline insulin dose for the degludec
U200 and glargine U300 treatment arms was 42.7 ± 29.5 U
and 42.2 ± 29.1 U, respectively. At the start of treatment, the
observed mean±SD basal insulin dose was 35.1 ± 23.8 U in
the degludec U200 group and 42.4 ± 29.2 U in the glargine
U300 group. At the end of treatment, the observed mean±SD
dosewas 66.6 ± 48.5U for the degludec U200 group and 73.0
± 48.5 U for the glargine U300 group (Fig. 7).
Adverse events and body weight
The number of adverse events per 100 person-years of expo-
sure (PYE) was 367.3 in the degludec U200 group and 365.4
per 100 PYE in the glargine U300 group; the corresponding
rate of serious adverse events was 27.3 per 100 PYE vs 25.7
per 100 PYE, respectively (ESM Table 4). The most frequent
adverse events (≥5%) reported were nasopharyngitis, upper
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Fig. 6 HbA1c, FPG and fasting SMBG over time. (a) HbA1c over the
study period. Estimated treatment difference from baseline to end of
treatment for degludec U200 vs glargine U300 was −1.07 mmol/mol
(95% CI −1.94, −0.20) (−0.10% [95% CI −0.18, −0.02]). (b) FPG over
the study period. Estimated treatment difference from baseline to end of
treatment for degludec U200 vs glargine U300 was −0.62 mmol/l (95%
CI −0.82, −0.43). (c) SMBG over the study period. Estimated treatment
difference from baseline to end of treatment for degludec U200 vs
glargine U300 was −0.18 mmol/l (95% CI −0.37, 0.01). Data are present-
ed as mean±SEM, with the number of participants (n) shown below each
graph. Vertical dotted lines illustrate the end of the titration period (week
16) and the beginning of the maintenance period (week 52). According to
the protocol, all participants were not required to complete all visits in the
variable maintenance period and therefore the number of participants at
each week decreased during this period
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respiratory tract infection and diarrhoea. Serious adverse
events attributed to hypoglycaemia during the trial were rela-
tively infrequent (8 events [0.72 events/100 PYE] for
degludec U200 and 21 events [1.89 events/100 PYE] for
glargine U300). A total of seven participants (all on treatment)
died in the degludec U200 group and nine (six on treatment)
died in the glargine U300 group, of which no deaths were
attributed to hypoglycaemic events or the trial products.
At the end of treatment, the observed change from baseline in
body weight was higher in the degludec U200 group compared
with the glargine U300 group (mean±SD: 2.9 ± 5.2 kg vs 1.7 ±
5.8 kg), with an estimated treatment difference of 1.18 kg (95%
CI 0.60, 1.75; post hoc analysis).
Discussion
In this open-label, randomised, treat-to-target trial in individuals
with type 2 diabetes treated with insulin, administration of
degludec U200 resulted in no significant difference in the rate
of overall symptomatic hypoglycaemia but it did result in a nomi-
nally significantly lower rate of nocturnal symptomatic and severe
hypoglycaemia during the maintenance period compared with
glargine U300. In the total treatment period, the rate of
hypoglycaemia was lower with degludec U200 for all three
hypoglycaemia endpoints compared with glargine U300.
Similarly, post hoc analyses showed that a lower proportion of
participants experienced all three hypoglycaemia endpoints
during the maintenance and total treatment periods. These
hypoglycaemia results were achieved in the present trial without
compromising glycaemic control.
Although the rate of overall symptomatic hypoglycaemia
during themaintenance period (primary endpoint) was lowerwith
degludec U200 compared with glargine U300, the difference did
not reach statistical significance. Thus, it was not possible to rule
out the possibility of no effect of degludec U200 compared with
glargine U300. However, the 95% CI for the RR, from 0.73 to
1.06, indicates no clinically significant harmwith degludecU200.
The BRIGHT trial was the first randomised clinical trial that
compared degludec U100 with glargine U300 in insulin-naive
individuals [21]. The results from BRIGHT demonstrated a
comparable primary outcome of glycaemic control along with
similar rates and proportions of participants experiencing
hypoglycaemia (any-time and nocturnal) with glargine U300 vs
degludec U100 in both the total treatment period (24 weeks) and
the maintenance period (12 weeks). However, a lower rate and
proportion of participants experienced any-time hypoglycaemia
during the titration period (12 weeks) with glargine U300 than
with degludec U100. The same results for the titration period
were not observed in CONCLUDE. Because BRIGHT was
undertaken in insulin-naive individuals without a history of
severe hypoglycaemia or hypoglycaemia unawareness, there
were not enough severe hypoglycaemic events to evaluate this
outcome. The higher rates of severe hypoglycaemic events in the
insulin-experienced population of CONCLUDE, who had at
least one hypoglycaemia risk factor (including a history of severe
hypoglycaemia), permitted an evaluation of these events. In
terms of the trial design, CONCLUDE had longer durations of
trial, titration period and maintenance period than BRIGHT. The
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88
Time (weeks)
Degludec U200 (n):
Glargine U300 (n):
40
60
80
100
120
D
a
ily
 o
b
s
e
rv
e
d
 i
n
s
u
lin
 d
o
s
e
 (
U
)
0
775 764 765 755 755 747 631 520 419 311 194 9 735 731 727 723 710 716 711 706 700 703
767 756 758 754 740 742 623 522 415 314 187 16 737 732 728 723 711 709 710 705 707 704
Degludec U200
Titration
period
16 weeks
Variable maintenance
period
Up to 36 weeks
Maintenance
period
36 weeks
Glargine U300Fig. 7 Basal insulin dose over
time. Data are presented as mean
±SEM, with the number of
participants (n) shown below the
graph. Vertical dotted lines
illustrate the end of the titration
period (week 16) and the
beginning of the maintenance
period (week 52). According to
the protocol, all participants were
not required to complete all visits
in the variable maintenance
period and therefore the number
of participants at each week
decreased during this period
Diabetologia (2020) 63:698–710 707
two trials also had different primary endpoints: hypoglycaemia
for CONCLUDE andHbA1c for BRIGHT. Furthermore, the two
trials used different definitions of hypoglycaemia with different
blood glucose levels (<3.1 mmol/l for CONCLUDE vs
≤3.9 mmol/l or <3.0 mmol/l for BRIGHT) and had different
titration algorithms. Target fasting SMBG in BRIGHT was
4.4–5.6 mmol/l, while in CONCLUDE the target was 4.0–
5.0 mmol/l. Finally, individuals treated with sulfonylureas were
excluded from CONCLUDE while they were included in
BRIGHT (65.7% of participants at baseline).
Previous studies have demonstrated that glargine U300 has a
weight benefit compared with glargine U100 [15–20]. During the
CONCLUDE trial a greater increase in body weight was
observed with degludec U200 compared with glargine U300.
This trial has several limitations. The requirement to amend the
protocol and include an additional maintenance period added
complexity to the trial. However, the change in protocol and trial
design (i.e. the change in the glycaemic data collection system)
was essential to protect the safety of the trial participants.
Ultimately, we believe that these protocol revisions did not impact
the scientific integrity of the trial because few participants (n= 25
[1.6%]) did not re-consent for the new maintenance period
(between the day that the protocol amendment was implemented
and each participant’s individual day of initiating the new main-
tenance period; the remaining participants were withdrawn or lost
to follow-up prior to the protocol amendment). However, we
cannot exclude that unknown confounding factors could have
been introduced that may have biased the perception of the inves-
tigators and participants, possibly affecting the conduct of the trial.
In addition, it is important to note that although the
MyGlucoHealth meter led to inaccurate blood glucose measure-
ments, all participants used this system for the entire titration
period thus the data reporting pattern was the same for both treat-
ment groups. Moreover, the reporting of severe hypoglycaemia
was not influenced by the inaccurate measurement, as these
events were classified according to the ADA definition (requiring
third-party assistance) andwere externally adjudicated throughout
the trial. Furthermore, degludec U200 and glargine U300 were
compared in a controlled clinical trial setting, which limits the
generalisability to routine clinical practice where individuals
may have chronically higher HbA1c levels despite basal insulin
use, receive less support to prevent hypoglycaemia as well as use
different titration targets and have issues regarding adherence.
However, a recent literature review found that rates of
hypoglycaemia overlap substantially in real-world settings and
clinical trial settings [30]. Finally, data concerning the
sociodemographic aspects (such as occupation, education level,
etc.), which could potentially impact hypoglycaemia, were not
collected during the trial.
Our trial has several strengths, including the large enrolment of
insulin-treated individuals with a long duration of diabetes. The
CONCLUDE population represents a more accurate reflection of
patients seen in clinical practices than most published insulin
randomised controlled trials where individuals with
hypoglycaemia risk factors are typically excluded [9, 14–21].
Furthermore, the duration of the trial was relatively long,
compared with most other clinical trials in this patient population,
with a total treatment period of up to 88 weeks. This allowed for
the assessment of glycaemic and hypoglycaemia outcomes over a
longer time period than other trials.
In conclusion, the rate of overall symptomatic hypoglycaemia
with degludec U200 was not significantly lower than with
glargine U300 in the maintenance period. The rate of nocturnal
symptomatic and severe hypoglycaemia were nominally signifi-
cantly lower with degludec during the maintenance period
compared with glargine U300.
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